These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology. Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160 [TBL] [Abstract][Full Text] [Related]
4. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage. Troyer C; Nguyen W; Xie A; Wimer D J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324 [TBL] [Abstract][Full Text] [Related]
5. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541 [TBL] [Abstract][Full Text] [Related]
6. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Stevens VM; Trujillo T; Mueller SW; MacLaren R; Reynolds PM; Kiser TH Clin Appl Thromb Hemost; 2019; 25():1076029619896619. PubMed ID: 31876159 [TBL] [Abstract][Full Text] [Related]
8. Real-world utilization of andexanet alfa. Brown CS; Scott RA; Sridharan M; Rabinstein AA Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672 [TBL] [Abstract][Full Text] [Related]
9. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. Abdulrehman J; Eikelboom JW; Siegal DM Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083 [TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA. Heo YA Drugs Ther Perspect; 2018; 34(11):507-512. PubMed ID: 30459509 [TBL] [Abstract][Full Text] [Related]
11. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series. Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614 [TBL] [Abstract][Full Text] [Related]
12. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays. Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587 [TBL] [Abstract][Full Text] [Related]
18. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies. Escolar G; Diaz-Ricart M; Arellano-Rodrigo E Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000 [TBL] [Abstract][Full Text] [Related]
19. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Stevens VM; Trujillo TC; Kiser TH; MacLaren R; Reynolds PM; Mueller SW Clin Appl Thromb Hemost; 2021; 27():10760296211039020. PubMed ID: 34541920 [TBL] [Abstract][Full Text] [Related]
20. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]